Editas Medicine Inc. (EDIT)

$5.55

-0.06

(-1.07%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Editas Medicine Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.88M → 60.04M (in $), with an average increase of 68.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -45.01M → -18.87M (in $), with an average increase of 138.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 77.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 328.9%

Performance

  • $5.53
    $5.68
    $5.55
    downward going graph

    0.45%

    Downside

    Day's Volatility :2.64%

    Upside

    2.2%

    downward going graph
  • $5.55
    $11.91
    $5.55
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :53.4%

    Upside

    53.4%

    downward going graph

Returns

PeriodEditas Medicine Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-31.33%
-0.7%
0.0%
6 Months
-15.0%
6.6%
0.0%
1 Year
-30.4%
3.7%
-1.5%
3 Years
-83.58%
14.0%
-21.8%

Highlights

Market Capitalization
478.6M
Book Value
$4.27
Earnings Per Share (EPS)
-2.02
PEG Ratio
0.0
Wall Street Target Price
15.86
Profit Margin
-196.13%
Operating Margin TTM
-39.9%
Return On Assets TTM
-20.87%
Return On Equity TTM
-43.17%
Revenue TTM
78.1M
Revenue Per Share TTM
1.03
Quarterly Revenue Growth YOY
818.6999999999999%
Gross Profit TTM
-155.2M
EBITDA
-163.1M
Diluted Eps TTM
-2.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.66
EPS Estimate Next Year
-2.74
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.6

Analyst Recommendation

Buy
    54%Buy
    41%Hold
    4%Sell
Based on 24 Wall street analysts offering stock ratings for Editas Medicine Inc.(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
10
9
11
Sell
1
2
2

Analyst Forecast

What analysts predicted

Upside of 185.77%

Current $5.55
Target $15.86

Company Financials

FY18Y/Y Change
Revenue
31.9M
↑ 132.64%
Net Income
-110.0M
↓ 8.62%
Net Profit Margin
-344.28%
↑ 532.21%
FY19Y/Y Change
Revenue
20.5M
↓ 35.71%
Net Income
-123.5M
↑ 12.29%
Net Profit Margin
-601.36%
↓ 257.08%
FY20Y/Y Change
Revenue
90.7M
↑ 341.93%
Net Income
-109.4M
↓ 11.38%
Net Profit Margin
-120.59%
↑ 480.77%
FY21Y/Y Change
Revenue
25.5M
↓ 71.85%
Net Income
-185.1M
↑ 69.18%
Net Profit Margin
-724.66%
↓ 604.07%
FY22Y/Y Change
Revenue
19.7M
↓ 22.83%
Net Income
-204.4M
↑ 10.4%
Net Profit Margin
-1.0K%
↓ 312.03%
FY23Y/Y Change
Revenue
78.1M
↑ 296.32%
Net Income
-153.2M
↓ 25.02%
Net Profit Margin
-196.13%
↑ 840.56%
Q3 FY22Q/Q Change
Revenue
42.0K
↓ 99.34%
Net Income
-53.9M
↑ 2.39%
Net Profit Margin
-128.4K%
↓ 127581.6%
Q4 FY22Q/Q Change
Revenue
6.5M
↑ 15461.9%
Net Income
-55.0M
↑ 2.04%
Net Profit Margin
-842.01%
↑ 127567.51%
Q1 FY23Q/Q Change
Revenue
9.9M
↑ 50.72%
Net Income
-45.6M
↓ 17.2%
Net Profit Margin
-462.56%
↑ 379.45%
Q2 FY23Q/Q Change
Revenue
2.9M
↓ 70.69%
Net Income
-40.3M
↓ 11.58%
Net Profit Margin
-1.4K%
↓ 933.01%
Q3 FY23Q/Q Change
Revenue
5.3M
↑ 84.83%
Net Income
-45.0M
↑ 11.74%
Net Profit Margin
-843.68%
↑ 551.89%
Q4 FY23Q/Q Change
Revenue
60.0M
↑ 1025.36%
Net Income
-18.9M
↓ 58.08%
Net Profit Margin
-31.43%
↑ 812.25%
FY18Y/Y Change
Total Assets
420.4M
↑ 12.63%
Total Liabilities
184.2M
↑ 11.53%
FY19Y/Y Change
Total Assets
508.9M
↑ 21.05%
Total Liabilities
246.4M
↑ 33.78%
FY20Y/Y Change
Total Assets
572.6M
↑ 12.52%
Total Liabilities
179.0M
↓ 27.36%
FY21Y/Y Change
Total Assets
677.5M
↑ 18.32%
Total Liabilities
123.8M
↓ 30.82%
FY22Y/Y Change
Total Assets
514.3M
↓ 24.08%
Total Liabilities
153.6M
↑ 24.06%
FY23Y/Y Change
Total Assets
499.2M
↓ 2.95%
Total Liabilities
150.1M
↓ 2.33%
Q3 FY22Q/Q Change
Total Assets
531.0M
↓ 8.57%
Total Liabilities
116.3M
↑ 0.75%
Q4 FY22Q/Q Change
Total Assets
514.3M
↓ 3.15%
Total Liabilities
153.6M
↑ 32.13%
Q1 FY23Q/Q Change
Total Assets
464.1M
↓ 9.76%
Total Liabilities
146.6M
↓ 4.56%
Q2 FY23Q/Q Change
Total Assets
542.0M
↑ 16.77%
Total Liabilities
142.0M
↓ 3.13%
Q3 FY23Q/Q Change
Total Assets
504.7M
↓ 6.88%
Total Liabilities
144.2M
↑ 1.52%
Q4 FY23Q/Q Change
Total Assets
499.2M
↓ 1.09%
Total Liabilities
150.1M
↑ 4.07%
FY18Y/Y Change
Operating Cash Flow
-45.7M
↑ 385.37%
Investing Cash Flow
-53.1M
↓ 71.12%
Financing Cash Flow
86.9M
↓ 43.74%
FY19Y/Y Change
Operating Cash Flow
-40.7M
↓ 11.02%
Investing Cash Flow
12.3M
↓ 123.08%
Financing Cash Flow
131.8M
↑ 51.63%
FY20Y/Y Change
Operating Cash Flow
-179.8M
↑ 342.21%
Investing Cash Flow
-140.5M
↓ 1246.93%
Financing Cash Flow
224.1M
↑ 70.02%
FY21Y/Y Change
Operating Cash Flow
-163.8M
↓ 8.92%
Investing Cash Flow
-54.5M
↓ 61.24%
Financing Cash Flow
282.1M
↑ 25.87%
FY22Y/Y Change
Operating Cash Flow
-177.3M
↑ 8.27%
Investing Cash Flow
114.1M
↓ 309.43%
Financing Cash Flow
1.3M
↓ 99.54%
Q3 FY22Q/Q Change
Operating Cash Flow
-48.0M
↑ 26.84%
Investing Cash Flow
89.2M
↓ 2329.56%
Financing Cash Flow
80.0K
↓ 78.2%
Q4 FY22Q/Q Change
Operating Cash Flow
-42.3M
↓ 11.94%
Investing Cash Flow
-27.5M
↓ 130.85%
Financing Cash Flow
619.0K
↑ 673.75%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.8M
↓ 15.39%
Investing Cash Flow
23.3M
↓ 184.52%
Financing Cash Flow
3.8M
↑ 510.82%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.7M
↑ 8.23%
Investing Cash Flow
13.0M
↓ 44.2%
Financing Cash Flow
117.5M
↑ 3008.3%
Q3 FY23Q/Q Change
Operating Cash Flow
-35.5M
↓ 8.4%
Investing Cash Flow
-102.8M
↓ 892.02%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Editas Medicine Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Editas Medicine Inc.
Editas Medicine Inc.
-27.33%
-15.0%
-30.4%
-83.58%
-78.26%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Editas Medicine Inc.
Editas Medicine Inc.
NA
NA
0.0
-2.66
-0.43
-0.21
NA
4.27
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Editas Medicine Inc.
Editas Medicine Inc.
Buy
$478.6M
-78.26%
NA
-196.13%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Vanguard Group Inc

    10.45%

  • BlackRock Inc

    9.99%

  • Deep Track Capital, LP

    8.70%

  • State Street Corporation

    7.07%

  • Woodline Partners LP

    3.99%

  • Dimensional Fund Advisors, Inc.

    2.93%

Corporate Announcements

  • Editas Medicine Inc. Earnings

    Editas Medicine Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Organization
Editas Medicine Inc.
Employees
265
CEO
Dr. Gilmore O'Neill M.D.
Industry
Health Technology

Discover More

FAQs